Onyx Provides Detail On Frontline Strategy For Kyprolis
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx supplied details about its clinical plans to enable frontline approval for Kyprolis to treat multiple myeloma and to effectively compete against well-established proteasome inhibitor competitor Velcade. It also elaborated further on its pipeline plans and deal-making strategy at an analyst day on March 14.
You may also be interested in...
R&D In Brief: Amgen, Arrowhead, Rigel, Coherus, Achillion
Arrowhead readies to advance its RNAi candidate for hepatitis B, while data on Achillion’s ‘3102 plus Sovaldi prepare the firm to start trials of its proprietary HCV combo. Coherus advances with a Humira biosimilar and Amgen will file Kyprolis for new indication despite failed study, while Rigel dry-eye failure has the firm refocusing on fostamatinib.
With Kyprolis Advancing, Millennium Stakes Faith In Oral Velcade Successor
Takeda/Millennium’s oral weekly proteasome inhibitor MLN9708 looked effective with a mild neuropathy profile in a new myeloma study presented at the American Society of Hematology meeting, and Takeda has committed to large Phase III trials. There’s no time to lose – mid-stage studies presented for Onyx’ rival Kyprolis, currently approved for relapsed myeloma, support moving that drug to the frontline.
Social Norms Shift, But U.S. Rules On Cannabis-Related Drug R&D Lag Behind
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?